The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the management of cancer patients, but the emergence of ICI-related endocrinopathies (IREs) has introduced new clinical challenges. Despite worldwide recognition of these adverse effects, data from the Middle East is scarce....

Descripció completa

Dades bibliogràfiques

Autors principals:	Fateen Ata, Adeel Ahmad Khan, Emad Algorani, Amr Faisal Musaed Alsharafi, Reham Abo Shdid, Mohammad Nofal, Ayman R. Ibrahim, Loai Abdullah, Khalil Youssef El Annan, Tareq Emad Hawash Al-Bkoor, Kakil Ibrahim Rasul, Tarik Elhadd, Haval Surchi
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-12-01
Col·lecció:	BMC Medicine
Matèries:	Immune checkpoint inhibitors Pembrolizumab Nivolumab Atezolizumab Ipilimumab Durvalumab
Accés en línia:	https://doi.org/10.1186/s12916-024-03812-2
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!